Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Paroxysmal Nocturnal Hemoglobinuria
Clinical Trial
NCT04085601Last updated: 12/4/2025
APLS
Apellis Pharmaceuticals, Inc.
